Malaria melatonin receptor signaling as a novel drug target

疟疾褪黑激素受体信号传导作为新的药物靶点

• 批准号: 9033819
• 负责人: ANDREW P THOMAS
• 金额: $ 43.15万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-16 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9033819
• 关键词: Affect; Affinity; Affinity Chromatography; Anemia; Antimalarials; Binding Proteins; Biological Assay; Biology; Blood; Calcium; Calcium Signaling; Cell Culture Techniques; Cell Cycle; Cell Cycle Progression; Cell Proliferation; Cells; Cerebral Malaria; Chemicals; Child; Circadian Rhythms; Clinical; Cloning; Combined Modality Therapy; Complex; Cyclic AMP; Cytolysis; Data; Development; Disease; Dose; Drug Industry; Drug Targeting; Drug effect disorder; Erythrocytes; Family; Fever; Flow Cytometry; GTP-Binding Proteins; Gel; Goals; Gold; Homeostasis; Hormone Receptor; Hormones; Hour; Human; Image; Immune system; In Vitro; Infection; Inositol; Lead; Libraries; Life; Life Cycle Stages; Liver; Malaria; Melatonin; Melatonin Receptors; Modeling; Morbidity - disease rate; Nature; Organ failure; Parasitemia; Parasites; Parasitology; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Pineal gland; Plant Resins; Plasmodium; Plasmodium falciparum; Play; Production; Publications; Reagent; Receptor Gene; Receptor Signaling; Resistance; Resistance development; Rodent; Rodent Model; Role; Second Messenger Systems; Serotonin; Signal Pathway; Signal Transduction; Specificity; Staging; Symptoms; Synthesis Chemistry; Techniques; Testing; Therapeutic; Time; Treatment Efficacy; Validation; Work; combat; fluorescence imaging; gene cloning; in vivo; interest; mortality; multidisciplinary; new therapeutic target; novel; receptor; research study; response; second messenger; small molecule; small molecule inhibitor; targeted treatment; tool; vector mosquito

DESCRIPTION (provided by applicant): Malaria is a leading cause of morbidity and mortality in the Third World and resistance of Plasmodium parasites to antimalarial treatments is a significant and growing problem. Novel drug targets and treatment approaches are urgently required, but this is an under-resourced problem in the pharmaceutical industry. The purpose of this proposal is to validate a malarial signaling pathway as a novel drug target, using a subset of compounds with antimalarial activity recently released by a major pharmaceutical company, together with a related group of compounds already validated for other clinical uses. The proposed target is a malarial melatonin receptor (pMTR) that is postulated to subvert the host hormone melatonin to regulate parasite proliferation and entrain the Plasmodium cell cycle to be synchronized with the host circadian rhythm. Validation of pMTR as a potential target for small molecule drug therapy would represent a paradigm shift, both in terms of the novel pathway identified and the proposed mechanism of therapeutic action. The present work is focused on the red blood cell (RBC) stage of P. falciparum infection, which is responsible for the predominant disease symptoms, including anemia, cerebral malaria, multi-organ failure and, significantly, periodic fevers that occur on a 48 h cycle. Our previous studies have provided evidence that melatonin can initiate an intracellular calcium signaling cascade involving the second messenger IP3, leading to enhanced parasitemia and stimulating progression through the cell cycle. We hypothesize that the Plasmodia melatonin receptor (pMTR) represents a novel antimalarial drug target to decrease proliferation and synchronization of the RBC cycle. The specific aims of the proposed project are: 1. To validate pMTR as a potential small molecule chemical target and assess the effects of putative pMTR modulators on P. falciparum proliferation and synchronization. These studies will determine an initial activity profile and elucidate the mechanism of drug action, while at the same time providing additional information on the pMTR signaling pathway. 2. To develop chemical probe-derived affinity reagents to identify the pMTR protein, with the eventual goal to annotate and clone the gene. 3. To determine the efficacy of pMTR modulators in combination with established antimalarial drugs that are not thought to act through the pMTR calcium signaling pathway. 4. To examine the effect of the small molecule inhibitors of pMTR identified in Aim 1 in vivo using rodent models, in order to further assess the viability of pMTR as a potential small molecule drug target. The work will be carried out by a multidisciplinary team, with expertise in calcium and G-protein signaling, malaria biology, parasitology, chemical biology and medicinal chemistry. Techniques include live-cell fluorescence imaging, imaging flow cytometry, in vivo malaria models, and synthetic chemistry.

描述（由申请人提供）：疟疾是第三世界发病率和死亡率的主要原因，疟原虫对抗疟治疗的耐药性是一个重要且日益严重的问题。迫切需要新的药物靶点和治疗方法，但这是制药行业资源不足的问题。该提案的目的是验证疟疾信号通路作为一种新的药物靶点，使用一个子集， 一家大型制药公司最近发布了具有抗疟疾活性的化合物，以及一组已被验证可用于其他临床用途的相关化合物。建议的目标是疟疾褪黑激素受体（pMTR），假定颠覆宿主激素褪黑激素调节寄生虫增殖和夹带疟原虫细胞周期与宿主昼夜节律同步。pMTR作为小分子药物治疗的潜在靶点的验证将代表一种范式转变，无论是在所鉴定的新途径还是所提出的治疗作用机制方面。目前的工作集中在红细胞（RBC）阶段的恶性疟原虫感染，这是负责的主要疾病症状，包括贫血，脑型疟疾，多器官衰竭，并显着，周期性发热，发生在48小时的周期。我们以前的研究提供了证据表明，褪黑激素可以启动细胞内钙信号级联涉及第二信使IP3，导致增强寄生虫血症和刺激通过细胞周期的进展。我们假设疟原虫褪黑激素受体（pMTR）代表了一种新的抗疟药物靶点，以减少红细胞周期的增殖和同步化。拟议项目的具体目标是：1。验证pMTR作为潜在的小分子化学靶标，并评估推定的pMTR调节剂对恶性疟原虫增殖和同步化的影响。这些研究将确定初始活性特征并阐明药物作用机制，同时提供有关pMTR信号通路的额外信息。2.开发化学探针衍生的亲和试剂来鉴定pMTR蛋白，最终目标是注释和克隆该基因。3.确定pMTR调节剂与公认的抗疟药物（认为不通过pMTR钙信号通路发挥作用）联合使用的疗效。4.为了使用啮齿动物模型在体内检查Aim 1中鉴定的pMTR的小分子抑制剂的作用， 为了进一步评估pMTR作为潜在的小分子药物靶标的可行性。这项工作将由一个多学科团队进行，他们在钙和G蛋白信号传导方面具有专业知识， 疟疾生物学、寄生虫学、化学生物学和药物化学。技术包括活细胞荧光成像、成像流式细胞术、体内疟疾模型和合成化学。